Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- (-) Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 57 Results
Ready, Fire, Aim: How Not to Approach COVID Pricing Discussions
NPC raises concerns about various approaches to considering pricing for COVID-19 treatments.
Evolution of the AMCP Format for Formulary Submissions: Yesterday, Today and Tomorrow
The ongoing development of vaccines and treatments for COVID-19 is raising hopes as the world awaits the return to a normal way of life. But as seen in the past decades in the fight against cancer,…
NPC in Health Affairs: It's Time to Talk COVID-19 Treatment Prices
In an article on the Health Affairs Blog, National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois considers questions about COVID-19 treatments and prices and lays out a roadmap to…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Experts Advise Including Productivity in Value Assessment Frameworks – When Included, It Can Make a Difference
NPC researchers sought to assess if productivity is included in VAF analyses, when included, does it change the value assessment of an intervention, and if including productivity could change health…
Valuing Innovation in the Current and Post-Pandemic World
Biopharmaceutical industry experts gathered for a panel discussion at the eyeforpharma Virtual Conference to explore how the value of innovation, productivity and preparedness might change as a…
In Social Distancing, Finding Closeness in Community
In a video, National Pharmaceutical Council President and CEO Dan Leonard discusses social distancing and the importance of community during the COVID-19 pandemic.
Getting Value Right by Considering the Full Range of Benefits for Patients and Caregivers
A study in Health Affairs considers how health care decision-makers can incorporate the benefits associated with a medical treatment when assessing its societal value.
What's Really Behind Discrepancies in Coverage Decisions?
National Pharmaceutical Council President and CEO Dan Leonard discusses research that uncovers the reasons for discrepancies in coverage decisions.
Are Value-based Arrangements the Answer We’ve Been Waiting For?
A study by NPC suggests that while value-based arrangements can be one of many tools that payers leverage to address rising costs, it is also important to recognize the strengths and limitations…
How Do We Place a Value on Indirect Treatment Benefits Like Quality of Life?
A study from NPC and RTI Health Solutions evaluated how institutional barriers prevent the inclusion of broader individual and societal benefits associated with new health care innovations from being…
Considering the Needs of Older Patients in Value Assessments
When we consider health care value, how can we assess the challenges faced by older patients with multiple diseases and their caregivers when making unique choices about their treatment options? It’s…
Six Ways ICER Changes Benefit the Payer, Not the Patient
NPC Executive Vice President and Chief Science Officer Robert W. Dubois, MD, PhD, examines what more is needed to balance stakeholder needs and ensure that patients are an integral part of the value…
Latest ICER Report Relies on Incomplete Evidence, Inadequate Analyses
It’s troubling to see a new report from the Institute for Clinical and Economic Review (ICER) that used incomplete evidence and inadequate analyses.
More Than Just One Number: Assessing The Value of Innovative Treatments
In a commentary for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and CEO Dan Leonard takes a closer look at what changes are needed to ensure that value assessments can…
NPC Weighs in on ICER’s Approaches to Valuing Cures
Within the last few years, we’ve seen the development of treatments to cure specific types of blindness, cancers and hepatitis C. In coming years, we’re anticipating the Food and Drug Administration…
Value Assessments: Incorporating Patient Benefits and Perspectives in ICER Reviews of Allergy and Asthma Treatments
Tonya Winders, CEO and President, Allergy & Asthma Network (AAN), discusses her involvement in the peanut allergy value assessment process and shares her experiences in working with her members…
NPC in AJMC: Why We Need Multiple Measures of Cost-Effectiveness in the US
In an editorial for The American Journal of Managed Care, NPC Chief Science Officer and Executive Vice President Dr. Robert Dubois explores the pitfalls of assigning only one organization the…
Key Takeaways From an ISPOR Panel on Creative Financing Proposals
An expert panel was convened at the ISPOR 2019 annual meeting to discuss the need for novel payment approaches to address the challenges that accompany transformative therapies.
NPC in Specialty Pharmacy Times: Creative Financing for Innovative, Curative Therapies
States are getting creative about how they can meet the health care needs of their citizens, especially when it comes to curative treatments for conditions with a high rate of prevalence. More…